Mirum Pharmaceuticals to Acquire Bluejay Therapeutics for Up to $820M

Mirum Pharmaceuticals, Inc.

Mirum pays $250M cash and up to 5.2M shares (≈$370M) at closing, plus up to $200M in milestone payments for Bluejay Therapeutics.
Acquisition adds brelovitug, a Phase 3 monoclonal antibody for chronic hepatitis D (HDV) with Breakthrough Therapy and PRIME designations.
Mirum also raised $200M in a PIPE from investors including Morgan Stanley, Leerink, Cantor, Raymond James, and Citizens JMP.
Top-line Phase 3 data for brelovitug expected in second half of 2026; BLA submission anticipated in first half of 2027.
Transaction expected to close in Q1 2026, subject to HSR clearance, stockholder approval, and other customary conditions.

item 1.01 item 3.02 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Mirum Pharmaceuticals, Inc. entered into Agreement and Plan of Merger and Reorganization with Bluejay Therapeutics, Inc. valued at an upfront amount of $250 million in cash and up to 5,196,009 shares of Company common stock (effective 2025-12-06).

Action: entry
Agreement: merger
Counterparty: Bluejay Therapeutics, Inc.
Value: an upfront amount of $250 million in cash and up to 5,196,009 shares of Company common stock
Effective: 2025-12-06

Exact text from the filing

On December 6, 2025, Mirum Pharmaceuticals, Inc. (the “Company”) entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Bjork Merger Sub I, Inc., a Delaware corporation and a direct wholly owned subsidiary of the Company (“Merger Sub I”), Bjork Merger Sub II, LLC, a Delaware limited liability company and a direct wholly owned subsidiary of the Company (“Merger Sub II” and, together with Merger Sub I, the “Merger Subs”), Bluejay Therapeutics, Inc., a Delaware corporation (“Target”), and Fortis Advisors LLC, a Delaware limited liability company, solely in its capacity as the representative, agent and attorney in fact of the Target security holders

View on SEC.gov

Browse all material agreements →

Mirum Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-310611

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.